Registered medicineWegovy
- Registered medicine (EMA)
- Studied in clinical trials*
- Doses from 0.25mg to 2.4mg
- Part of a program with lifestyle coaching and guidance
€200,99/month
Cancel monthly. If you decide not to start after your consultation, you get your money back right away.
Start the questionnaireWeekly injection
0.25mg – 2.4mg
Semaglutide
Novo Nordisk
How semaglutide works in your body.
Curbs appetite
Semaglutide mimics GLP-1, the hormone released after eating. Your brain gets the signal sooner: enough.
Fuller for longer
Your stomach empties more slowly, so you stay full longer after a meal and reach for snacks less often.
Studied in trials
The efficacy and safety of semaglutide 2.4 mg were studied in large clinical trials over 68 weeks.*
Your dose grows with you.
Starting low is not a detour but clinical guideline: your body adjusts and side effects stay manageable. Your doctor sets the pace.
0.25 mg
Weeks 1–4 · adjusting
Your body builds tolerance.
0.5 mg
Weeks 5–8 · building up
Appetite suppression becomes noticeable.
1 mg
From week 9 · maintenance
The steady dose for many clients.
1.7 – 2.4 mg
Optional
Only if a higher dose is needed.
Questions along the way? Just message your doctor or coach in the app.
Medication is one part of your program.
- Medical intake and oversight, a doctor assesses your situation and follows your progress
- Online lifestyle program covering nutrition, sleep, stress and exercise
- Personal treatment plan with dosing tailored to you
- Discreet home delivery, cooled and fast
Still deciding between treatments?
During the online consultation the doctor advises what suits you best.
Wegovy
Wondering whether treatment suits you?
Fill in the questionnaire, it takes about 10 minutes. A doctor reviews your situation and advises whether the treatment suits you.
Start the questionnaireNo obligation · cancel monthly* Refers to published clinical trials of semaglutide 2.4 mg over 68 weeks (STEP 1). Results vary per person and are no guarantee. Wegovy is a registered trademark of Novo Nordisk A/S. This page is intended to inform, not to promote medicines. Read the package leaflet before use. A doctor always assesses first whether treatment is medically appropriate.
Blog about medical weight loss
Read our articles about medical weight loss, lifestyle, nutrition, medication, obesity, exercise and healthy living.
Wegovy pil goedgekeurd in Europa: de eerste GLP-1 pil voor gewichtsbeheersing
De Europese Commissie heeft de Wegovy pil goedgekeurd als eerste GLP-1 pil voor gewichtsbeheersing in de EU. Wat is er precies goedgekeurd en wanneer komt de pil naar Nederland?
Ontsteking en obesitas: waar start de vicieuze cirkel?
Een diepgaande blik op de complexe relatie tussen obesitas en chronische ontsteking, hoe ze elkaar versterken, en hoe leefstijl en nieuwe behandelingen zoals GLP-1 medicatie deze cirkel kunnen doorbreken.
Wat je moet weten over GLP-1 medicatie (en wat er nog aankomt)
Ontdek de wetenschap achter GLP-1 medicatie: van semaglutide tot revolutionaire combinatiemiddelen die binnenkort op de markt komen en gewichtsverlies transformeren.